Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FEP633 + FEP600
- Development stage
- Preclinical
- Lead developer
- PRISM BioLab
- Modality
- Peptides, Small Molecules
01
Overview
FEP633 and FEP600 are preclinical-stage small molecule peptide mimetics (PepMetics) developed by PRISM BioLab for the treatment of urothelial carcinoma. FEP600 functions as a mimetic of the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), which competitively inhibits the protein-protein interaction (PPI) between eukaryotic translation initiation factor 4E (eIF4E) and eukaryotic translation initiation factor 4G1 (eIF4G1). By disrupting the formation of the eIF4F translation initiation complex, these compounds suppress the translation of oncogenic mRNAs involved in tumor growth and progression. FEP633 is a prodrug of FEP600, currently in the final stages of lead optimization. Preclinical studies in patient-derived xenograft (PDX) models of muscle-invasive and metastatic urothelial carcinoma have demonstrated that FEP600 possesses superior anti-tumor activity compared to standard-of-care cisplatin.
- Other names
- FEP633/FEP600
02
Targets
EIF4G1 (Eukaryotic translation initiation factor 4 gamma 1)
Beyond the preview
Go deeper on FEP633 + FEP600.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FEP633 + FEP600.